United Statesdenalitherapeutics.com
Denali Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative and lysosomal storage diseases. Headquartered in South San Francisco, the company’s research centers on improving drug delivery to the central nervous system to address conditions with high unmet medical need.
Denali’s approach leverages its proprietary Transport Vehicle (TV) technology designed to enable biologics and other modalities to cross the blood–brain barrier and reach targets in the brain. Its pipeline includes an investigational LRRK2 inhibitor program for Parkinson’s disease (in collaboration with Biogen), small‑molecule and biologic programs aimed at modulating neuroinflammation pathways such as RIPK1 (partnered with Sanofi), and enzyme replacement candidates engineered to enter the brain, including an iduronate‑2‑sulfatase program for Hunter syndrome (MPS II). The company is also advancing additional programs in disorders such as Alzheimer’s disease and ALS. Denali operates through a mix of internal R&D and strategic partnerships to progress candidates through clinical development.
None yet. When a new project in the record names Denali Therapeutics as owner, partner or investor, it shows here.
Lilly appoints Carole Ho and Adrienne Brown to Executive Committee, expands roles for Daniel Skovronsky and Jacob Van Naarden to drive growth in neuroscience and immunology.
